SEOUL, November 17 (AJP) - South Korea’s Celltrion has won a Brazilian federal government tender for Herzuma, its breast and gastric cancer biosimilar, for a seventh straight year. The deal secures exclusive supply of about 1 million vials through 2027, the company said Tuesday.
The tender covers about 80 percent of Brazil’s public trastuzumab market. Herzuma leads Brazilian prescriptions with about 50 percent market share, ahead of the original drug, according to IQVIA data cited by Celltrion.
Celltrion is also adding more drugs in Brazil.
Omlyclo, its omalizumab biosimilar, has taken about 26 percent of the private market since launching late last year. Eye treatment Eydenzelt and autoimmune drug Avtozma are set to launch by year-end.
Tags: Celltrion, Biosimilar, Brazil, Omlyclo, Eydenzelt, Avtozma, IQVIA, Market Share
The tender covers about 80 percent of Brazil’s public trastuzumab market. Herzuma leads Brazilian prescriptions with about 50 percent market share, ahead of the original drug, according to IQVIA data cited by Celltrion.
Celltrion is also adding more drugs in Brazil.
Omlyclo, its omalizumab biosimilar, has taken about 26 percent of the private market since launching late last year. Eye treatment Eydenzelt and autoimmune drug Avtozma are set to launch by year-end.
Tags: Celltrion, Biosimilar, Brazil, Omlyclo, Eydenzelt, Avtozma, IQVIA, Market Share
Copyright ⓒ Aju Press All rights reserved.